Yuki Kitaoka

Business Performance

Books

• Experimental Protocols for reactive oxygen species and reactive nitrogen species edited by Naoyuki Taniguchi and John Guttridge.
  Oxford Press
  Part I, Chapter III: Measurements for proteinaceous plasma antioxidants, low molecular weight antioxidants, and REDOX related compounds.: ADF/thioredoxin: purification of thioredoxin reductase/ thioredoxin assay (insulin reducing assay), Page61-64, 2000. Yuki Kitaoka and Junji Yodoi.
• Frontiers of reactive oxygen species in biology and medicine. edited by Kozi Asada and Toshikazu Yoshikawa.
  Excepta Medica, Elsevier Science B.V. Adult T cell leukemia-derived factor/human thioredoxin in retroviral infections., pp435-438, 1994 Yuki Kitaoka, Keizo Furuke, Satoshi Iwata, Norihiko Sato, Takahide Mori and Junji Yodoi.
• Frontiers of reactive oxygen species in biology and medicine. edited by Kozi Asada and Toshikazu Yoshikawa. Excepta Medica, Elsevier Science B.V.
  Possible involvement of adult T cell leukemia-derived factor (ADF)/human thioredoxin in growth inhibitory effects of a sulfhydryl oxidant, diamide., pp287-288, 1994. Norihiko Sato, Kazuhiro Nakamura, Yuki Kitaoka, Satoshi Iwata, Hiroshi Masutani, Toshiyuki Hori, Kinichiro Mori and Junji Yodoi.
• Microbial Infections: Role of Biological Response Modifiers. edited by Herrman Fridman. Plenum Press, New York ADF (adult T cell derived factor)/human thioredoxin and viral infection: possible new therapeutic approach., pp265-274, 1992. Hiroshi Masutani, Hajime Nakamura, Yasuyo Ueda, Yuki Kitaoka, Takumi Kawabe, Satoshi Iwata, Akira Mitsui, and Junji Yodoi.
• Cell Technology Supplement: Experimental Protocols for Reactive Oxygen Species
  (contributing author). Shujunsha. Contributed section: “Methods for Measuring Low-Molecular-Weight Compounds Related to Reactive Oxygen Species: ADF/Thioredoxin,” pp. 89–92, September 1994. Yuki Kitaoka and Junji Yodoi.
• Nippon Rinsho: Supplement, Syndrome by Medical Specialty,
  Vol. 1 (contributing author). Nippon Rinsho, Inc. Contributed section: “Endocrine Syndromes—Female Sexual Function: Polycystic Ovary Syndrome,” pp. 725–731, June 1993. Yuki Kitaoka and Takahide Mori.
• Nippon Rinsho, Vol. 51, Supplement: Clinical Statistics in Japan, Part 2 (contri
  buting author). Nippon Rinsho, Inc. Contributed section: “Clinical Statistics in Japan: Endocrine and Metabolic Diseases—Polycystic Ovary Syndrome,” pp. 172–181, January 1993. Yuki Kitaoka, Kenji Takakura, and Takahide Mori.

Review Articles

27 articles omitted.

Original Articles (Japanese)

27 articles omitted.

Original Articles (English)

• Uno-Eder K, Satoh-Asahara N, Hibiya M, Uno K, Uchino T, Morita K, Ishikawa T, Kaneko T, Yamakage H, Kitaoka Y, Sawa T, Tsukamoto K, Teramoto T.
  Understanding impacts of COVID-19 restrictions on glycemic control for patients with diabetes in Japan. J Diabetes Metab Disord. 2023 Sep 21;22(2):1695-1703.
• Tokushige M, Suginami H, Taniguchi F, Kitaoka Y.
  Laparoscopic surgery for endometriosis: a long-term follow-up. J Obstet Gynaecol Res. 2000 Dec;26(6):409-416.
• Sasada T, Nakamura H, Ueda S, Sato N, Kitaoka Y, Gon Y, Takabayashi A, Spyrou G, Holmgren A, Yodoi J.
  Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic Biol Med. 1999 Sep;27(5-6):504-514.
• Maruyama T, Sachi Y, Furuke K, Kitaoka Y, Kanzaki H, Yoshimura Y and Yodoi J.
  Induction of Thioredoxin, a Redox-Active Protein, by Ovarian Steroid Hormones during Growth and Differentiation of Endometrial Stromal Cells in Vitro.Endocrinology, 140, (1), pp365-372, 1999.
• Maruyama T, Kitaoka Y, Sachi Y, Nakanoin Y, Hirota K, Shiozawa T, Yoshimura Y, Fujii S and Yodoi J.
  Thioredoxin expression in the human endometrium during the menstrual cycle. Molecular Human Reproduction, 3 , (11), pp989-993, 1997.
• Yamabe T, Takakura K, Sugie K, Kitaoka Y, Takeda S, Okubo Y, Teshigawara K, Yodoi J, Hori T.
  Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15. Immunology. 1997 May;91(1):151-158.
• Sasada T, Iwata S, Sato N, Kitaoka Y, Hirota K, Nakamura K, Nishiyama A, Taniguchi Y, Takabayashi A, Yodoi J.
  Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity.J Clin Invest. 1996 May 15;97(10):2268-2276.
• Kobayashi F, Sagawa N, Nanbu Y, Kitaoka Y, Mori T, Fujii S, Nakamura H, Masutani H and Yodoi J.
  Biochemical and topological analysis of adult T-cell leukemia-derived factor, homologous to thioredoxin, in the pregnant human uterus. Molecular Human Reproduction, 10, (6), pp1603-1608, 1995.
• Doctoral Dissertation:
  Kitaoka Y, Sorachi K, Nakamura H, Masutani H, Mitsui A, Kobayashi F, Mori T, Yodoi J. Detection of adult T-cell leukemia-derived factor/human thioredoxin in human serum. Immunol Lett. 1994 Jul;41(2-3):155-61.
• Nakamura H, Matsuda M, Furuke K, Kitaoka Y, Iwata S, Toda K, Inamoto T, Yamaoka Y, Ozawa K, Yodoi J.
  Adult T cell leukemia-derived factor/human thioredoxin protects endothelialF-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol Lett. 1994 Sep;42(1-2):75-80.
• Kitaoka Y, Sachi Y and Yodoi J.
  Measurement of adult T cell leukemia-derived factor/human thioredoxin in sera from HTLV-I infected individuals. 1993 Annual Report of the Inst. Virus Res. Kyoto Univ., 36, pp47-48, 1994.
• Masutani H, Nakamura H, Ueda Y, Kitaoka Y, Kawabe T, Iwata S, Mitsui A, Yodoi J. ADF (adult T cell leukemia-derived factor)/human thioredoxin and viral infection: possible new therapeutic approach. Adv Exp Med Biol. 1992;319:265-74.
• Kitaoka Y, Kitaueda A, Ueda Y, Mitsui A and Yodoi J.
  Purification and partial amino acids sequencing of thioredoxin reductse from human placenta. 1991 Annual Report of the Inst. Virus Res. Kyoto Univ., 34, pp47-48, 1992.
• Sorachi K, Kitaoka Y, Nakamura H, Masutani H, Matsuda M, Ueda Y, Kumagai S, Imura H, Osame M and Yodoi J.
  Effect of inhibitors for ATL derived factor (ADF) / thioredoxin (TRX) and its reductase on the proliferation of PBL from HTLV-I associated myelopathy. 1991 Annual Report of the Inst. Virus Res. Kyoto Univ., 34, pp50-51, 1992.
• Ueda Y, Masutani H, Nakamura H, Kitaoka Y, Kawabe T, Iwata S, Mitsui A and Yodoi J.
  The effect of 13-cis retinoic acid on ADF (adult T cell leukemia derived factor) high producer cells. 1991 Annual Report of the Inst. Virus Res. Kyoto Univ., 34, pp51-52, 1992.
• Kitaoka Y, Nakamura H, Masutani H and Yodoi J.
  Adult T cell leukemia-derived factor/thioredoxin exists in human serum. 1990 Annual Report of the Inst. Virus Res. Kyoto Univ., 33, pp39-40, 1991.
• Kawabe T, Okamoto T, Mitsui A, Kitaoka Y, Nakamura H, Masutani H, Warren J. Leonard and Yodoi J.
  ADF/human thioredoxin regulates the interaction of NFκB with IL-2 Receptor α-chain enhancer. 1990 Annual Report of the Inst. Virus Res. Kyoto Univ., 33, pp38-39, 1991.